Publications Related to DecisionDx-UM

Aaberg, et al. (2014). Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clinical Opthalmology, 8, 2449-60.

Aaberg (2012). Practical approaches to needle biopsy and genetic diagnosis for ocular melanoma. Retina 2012: The Winds of Change. Lecture conducted from The American Academy of Ophthalmology, Chicago, IL.

Chappell, et al. (2012). Uveal Melanoma: molecular pattern, clinical features, and radiation response. American Journal of Ophthalmology, 227-32.

Correa & Augsburger. (2016). Independent prognostic significance of gene expression profile class and largest basal diameter of posterior uveal melanomas. American Journal of Ophthalmology, 162, 20-27 e1.

Correa & Augsburger. (2014). Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications. Graefe’s Archive for Clinical and Experimental Ophthalmology, 252(1), 131-5.

Demirci, et al. (2015). Gene expression profiling test of uveal melanoma: prognostic validation, in American Society of Ophthalmic Plastic & Reconstructive Surgery Fall Scientific Symposium: Las Vegas, NV.

Field & Harbour. (2014). Recent developments in prognostic and predictive testing in uveal melanoma. Current Opinion in Ophthalmology, 25(3), 234-9.

Gill & Char. (2012). Uveal melanoma prognostication: from lesion size and cell type to molecular class. Canadian Journal of Ophthalmology, 47, 246-253.

Harbour (2011). Molecular research in uveal melanoma: ushering in a new standard of care. Retina Times, 29, 36-7.

Harbour & Chen. (2013). The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLOS Currents Evidence on Genomic Tests. 2013 Apr 9 [last modified: 2013 Apr 9]. Edition 1.

Harbour (2010). Genomic Research in Uveal Melanoma. Retina Today, 67-69.

Onken, et al. (2012). Collaborative Ocular Oncology Group Report Number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophth, epub. The Collaborative Ocular Melanoma Study: An Overview

Onken, et al. (2010). An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. Journal of Molecular Diagnostics, 12(4), 461-8.

Onken, et al. (2006). Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. Journal of Molecular Diagnostics, 8, 567-73.

Onken, et al. (2004). Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Research, 64, 7205-9.

Plasseraud, et al. (2016). Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. Journal of Oncology, 2016. doi:10.1155/2016/5325762.

Walter, et al. (2016). Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmology, 134(7), 734-40.

Worley, et al. (2007). Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clinical Cancer Research, 13(5), 1466-71.


Publications Related to DecisionDx-PRAME

Field, et al. (2016). PRAME as an independent biomarker for metastasis in uveal melanoma. Clinical Cancer Research, 22, 1234-42.

Field, et al. (2016). Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget, 7, 59209-19.


Publications Related to DecisionDx-Melanoma

American Cancer Society. What are the survival rates for melanoma skin cancer by stage? American Cancer Society: Published October 29, 2013. Accessed October 29, 2013.

Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.

Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010;28:2452-9.

Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2011; 65(5): 1032-1047.

Coit DG, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma. Version 2.2013

Dhillon, et al. Gene expression profile signature (DecisionDx-Melanoma) to predict visceral metastatic risk in patients with Stage I and Stage II cutaneous melanoma. J Clin Oncol 2012;30(suppl; abstr 8543).

Gerami P, Cook RW, Russell MC, et al. Gene expression profile prediction of metastasis in thirty Stage III sentinel lymph node positive cutaneous melanoma tumors. Pigm Cell Melanoma R 2013;26(6):953.

Gerami, et al. Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma. Clin Cancer Res, 2015 21; 175.

Gerami, et al. Gene Expression Profiling for Molecular Staging of Cutaneous Melanoma in Patients Undergoing Sentinel Lymph Node Biopsy. J Am Acad Dermatol. 2015;72(5):780-785.

Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.

Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003; 238:528-35; discussion 35-7.

Lawson, D, et al. Gene expression profile of primary cutaneous melanomas to distinguish between low and high risk of metastasis.  J Clin Oncol 2013;31(suppl; abstr 9022).

Lawson D, Russell MC, Wilkinson J, et al. Development of a genetic signature that can accurately predict metastasis in Stage I and II cutaneous melanoma. Pigm Cell Melanoma R 2013;26(6):970.

Melanoma of the Skin (2010). In S.B. Edge (Ed.). American Joint Committee on Cancer (pp 325-344). New York, NY: Springer.

Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307-17.